Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis

• DOI: 10.1016/j.transci.2020.102821
• Publication Date: 2020-05-29T15:36:50Z
• Authors: Olgu Erkin Çınar; Başak Sayınalp; Elifcan Aladağ Ka...; Ayşe Avşar Karataş; Mustafa Velet; Ahmet Çağkan İnkaya; Nazmiye Ebru Erso...; Serpil Öcal; Salih Aksu; İbrahim Celaletti...; Nilgün Sayınalp; Osman İlhami Özcebe
• Keywords: Convalescent plasma; Cytokine Storm; Pandemic

During the ongoing COVID-19 pandemic due to SARS-CoV-2 virus of which evidence-based medical paradigms cannot be easily applied; difficult clinical decisions shall required particularly in 'difficult-to-treat' cases high risk group with associated comorbidities. Convalescent immune plasma therapy is a promising option as sort 'rescue' treatment syndrome, where miraculous antiviral drugs are not available yet. In this report, we aim convey our experience multi-task approach convalescent and anti-cytokine drug combination patient extremely challenging comorbidities including active myeloid malignancy, disseminated tuberculosis kidney failure.